Concept Elicitation Qualitative Study: Migraine Patient Experiences with Zavegepant

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Drug utilisation

  Evaluation of patient-reported outcomes
• Data collection methods:
  Primary data collection

Non-interventional study

• Non-interventional study design:
  Cross-sectional

Study drug and medical condition

• Name of medicine, other:
  Zavegepant (Zavzpret 10mg)
• Study drug International non-proprietary name (INN) or common name:
  RIMEGEPANT
• Anatomical Therapeutic Chemical (ATC) code:
  (N02CD08) zavegepant

  zavegepant
• Medical condition to be studied:
  Migraine

Population studied

• Short description of the study population:
  Adult participants (18 years old or older) who have used zavegepant (Zavzpret) at least once in the past 3 months and who reside in the United States. ; Participants who indicates or exhibits speaking or hearing difficulties, or lacks sufficient understanding of English, which would make a telephone conversation challenging will be excluded. ; Participants will be enrolled after providing their consent to participate in the study.
• Age groups:
  Adult and elderly population (≥18 years)
• Estimated number of subjects:
  20

Study design details

• Study design:
  This is a non-interventional, cross-sectional qualitative study involving one-on-one interviews with eligible participants.
• Main study objective:
  The study aims to assess patient´s perceptions and experiences regarding the use of zavegepant as an acute treatment treatment for migraine in the real-world setting in the United States.
• Setting:
  Participants will be identified and recruited from patient panels. ; A third-party vendor will recruit respondents from known migraine patients who have previously opted in to participating in research. ; Before providing their informed consent to participate in the study, participants will complete a screener to determine their eligibility and assess their overall experience (positive, neutral, or negative) with the medication. ; If eligible, an online conferencing/telephone interview will be conducted. ; The recruitment and data collection are expected to take place over a period of 10 weeks.